Dutch court halts Merck's subcutaneous Keytruda in several European countries
- STAT reports a Dutch court ordered Merck to stop manufacturing and marketing its subcutaneous Keytruda formulation in several European countries.
- Only the public lede was readable, so the plaintiff, grounds and scope are unverified here.
💡 Points
Subcutaneous Keytruda is Merck's main defense against the coming pembrolizumab biosimilar era, so any European delay hits that lifecycle plan directly. How long the order lasts and whether it is overturned on appeal matters more than the headline, and the case echoes the broader fight over SC hyaluronidase formulation patents.
STAT+: Merck suffers a setback in Europe over its new Keytruda formulation ↗